Citation
Shalhout SZ, Emerick KS, Kaufman HL, Silk AW, Thakuria M, Miller DM. A retrospective study of ipilimumab plus nivolumab in anti–PD-L1/PD-1–refractory Merkel cell carcinoma. J Immunother. 2022;45(7):299–302. doi:10.1097/CJI.0000000000000432.
Why this study matters
Anti–PD-1 and anti–PD-L1 therapies produce durable responses in many patients with advanced Merkel cell carcinoma, but approximately half of patients either fail to respond or eventually progress. Once resistance develops, evidence-based systemic options remain limited.
This study evaluated whether adding CTLA-4 blockade with ipilimumab to nivolumab could rescue patients whose disease had already proven refractory to prior checkpoint inhibition.
In this cohort, ipilimumab plus nivolumab produced no objective responses and was associated with substantial toxicity. The findings argue against assuming that dual checkpoint blockade can reliably overcome established anti–PD-1 or anti–PD-L1 resistance in advanced MCC.
The cohort at a glance
Patients with refractory advanced MCC
All had progressed after prior anti–PD-1 or anti–PD-L1 therapy.
No complete or partial responses
No patient achieved an objective response by RECIST v1.1 or immune-related RECIST.
Meaningful treatment toxicity
Severe immune-related adverse events occurred despite the absence of objective benefit.
What the study found
- No patient achieved a complete or partial response.
- Three patients had stable disease as their best response, but progression followed shortly thereafter.
- Median progression-free survival was 1.3 months.
- Median overall survival was 4.7 months.
- Nearly one-third of patients experienced a grade 3 or 4 immune-related adverse event.
Why salvage dual checkpoint blockade may fail
Established immune resistance
Once tumor progression occurs on PD-1 or PD-L1 blockade, adding CTLA-4 inhibition may not be sufficient to reverse the dominant resistance mechanisms.
Aggressive disease biology
Patients requiring second-line salvage therapy often have rapidly progressive disease and limited time for a delayed immune response.
Small retrospective cohorts
Rare-cancer studies are vulnerable to selection effects, but the complete absence of objective responses remains clinically important.
Toxicity without clear benefit
The risk-benefit balance becomes unfavorable when severe immune toxicity is common and response probability is very low.
Ipilimumab plus nivolumab should not be viewed as a reliably effective default salvage regimen after anti–PD-1 or anti–PD-L1 failure. Use should be selective, individualized, and weighed against clinical trials, local therapy, or other systemic strategies.
What this study does—and does not—show
- It provides real-world evidence of limited activity in a highly refractory population.
- It highlights the substantial toxicity of dual checkpoint blockade.
- It does not exclude benefit in every individual patient or in biologically distinct subgroups.
- It does not address the role of nivolumab plus ipilimumab in immunotherapy-naïve MCC.
- It underscores the need for better salvage strategies and prospective rare-cancer collaboration.
Authors
Sophia Z. Shalhout, Kevin S. Emerick, Howard L. Kaufman, Ann W. Silk, Manisha Thakuria, and David M. Miller.